India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
Hyderabad, April 6 (RAHNUMA): CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has announced positive top-line results from its Phase 3 trial of BP11, an investigational biosimilar to Omalizumab (marketed as Xolair). The study met all primary endpoints, demonstrating strong comparability with the reference drug in treating chronic spontaneous urticaria (CSU) at a 300 mg dose. Conducted across 608 patients at nearly 80 sites in Europe and India, the trial showed precise equivalence in itch severity reduction at Week 12, aligning with requirements of both the Food and Drug Administration and European Medicines Agency. The company said the results also confirmed comparable potency and consistent efficacy across dose levels, reinforcing BP11's potential across multiple indications, including CSU, allergic asthma, and chronic rhinosinusitis with nasal polyps. CuraTeQ plans to complete regulatory filings with the FDA and EMA by Q2 2026, aiming to expand access to cost-effective biologic therapies. Dr Arpitkumar Prajapati, head of clinical development, said "these Phase 3 results with narrow confidence intervals validate our clinical strategy and the team's execution in delivering a high-quality biosimilar. Detailed results will be submitted for regulatory review and presented at upcoming medical conferences." Dr. Disha Dadke, head of R&D and regulatory sciences, said "BP11 demonstrates comparable efficacy and safety to Xolair, paving the way for patient access to affordable treatment options. We are planning to complete filing of BP11 with both EMA and FDA by the end of Q2 2026."
New Delhi, April 5 (SocialNews.XYZ) India's pharmaceutical exports reached over $28 billion up to February in the current financial year, registering a growth of more than 5 per cent compared to the same period last year, a senior government official has said. Speaking at the inaugural session of the 'Chintan Shivir: Scaling Up Pharma Exports', the official highlighted that the growth was led by formulations, biologicals, vaccines, and Ayush products. "Despite global challenges, pharmaceutical exports have been among the few sectors to maintain growth momentum," he said, noting that exports ...Read More >
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. The approved drug is indicated as an adjunct to diet and exercise to improve glycemic control in adul ...Read More >
Hyderabad: The Chintan Shivir on the Pharmaceutical Sector, organized by the Pharmaceutical Export Promotion Council of India (PHARMEXCIL), with the support of the Ministry of Commerce & Industry, Government of India, concluded successfully today in Hyderabad. This event marked the continuation of the series of discussions, following successful editions in Chandigarh and Ahmedabad, and served as a platform for strengthening India's pharmaceutical export agenda. The inaugural session, chaired by Shri Rajesh Agrawal, IAS, Commerce Secretary, Department of Commerce and Industry, Ministry of Comm ...Read More >
Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global markets. Keytruda (generic name is pembrolizumab), manufactured and marketed by Merck & Co, is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of cancer. Under the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and ...Read More >
India's biotech ecosystem has also expanded significantly, now comprising over 2,500 startups, around 100 incubators, more than 600 research institutes, and over 200 accredited laboratories India's biotech sector is entering a new phase of global relevance, with the country's bioeconomy expanding from $10 billion in 2014 to $195 billion in 2026 and projected to touch nearly $300 billion by 2033, according to a report by Endiya Partners. The report, India's Biopharma Moment: Perspectives from DE ...Read More >
New Delhi: Commerce secretary Rajesh Agrawal Saturday asked the pharmaceutical industry to reduce its dependence on critical imported raw materials by meeting atleast 80-90% of domestic pharmaceutical requirements through indigenous production. Addressing an event in Hyderabad, he said while India exports to around 200 countries, there remains significant scope for expansion and resilience-building through a stronger market presence. Emphasising the need to navigate an increasingly uncertain and geopolitically volatile global environment, he said: "The importance of ensuring greater self-rel ...Read More >
Hyderabad: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, on Monday said it has reported positive top-line Phase 3 results for BP11, its investigational biosimilar to Xolair, or omalizumab.CuraTeQ said the study met all primary endpoints in patients with chronic spontaneous urticaria receiving the 300 mg dose, demonstrating high comparability with the reference product. The company said it plans to use the results to support regulatory submissions for chronic spontaneous urtica ...Read More >
Lucknow: This Diwali, residents of the city were exposed to decibel levels equivalent to noise made by a food blender switched on for hours. On Diwali night, noise levels exceeded standards at all sites, with highest value of 89.3 decibels (dB(A)) at Vikasnagar and the lowest of 75.8 dB (A) at Chowk on Diwali night, stated Indian Institute of Toxicology Research's air and noise quality assessment report for Lucknow during Diwali 2025, released on Thursday.Compared to the day before Diwali, noise levels at all four locations monitored by IITR increased by more than 15 units. After Vikasnagar, A ...Read More >
NEW DELHI, Apr 4 : "International Diabetes Federation" (IDF) President-elect, Dr Niti Pall, currently on India visit, called on Union Minister Dr Jitendra Singh, who is also a noted Professor of Medicine & Diabetes, and discussed, among other things, indigenous biosimilar Insulin production as well as Diabetes related indigenous biomanufacturing prospects. The meeting underscored the importance of strengthening India's capabilities in insulin manufacturing, particularly biosimilar insulins and Continuous Glucose Monitoring (CGM) instruments. The discussion brought into focus growing global c ...Read More >
New Delhi [India], June 8 (ANI): BJP MP Gulam Ali Khatana, who was part of the all-party parliamentary delegation to Europe, said that during their recently conclued visit they successfully communicated India's development story and its resolute stand against terrorism, particularly emanating from Pakistan. Highlighting the delegation's key discussions during the tour, Khatana told ANI, 'We discussed how we dismantled the terrorism factory in Pakistan by responding... We also talked about tourism infrastructure, G20 Summit, and projects like the six-lane roads, bridges, solar initiatives, our ...Read More >
New Delhi, Jun 27 (PTI) Biocon Ltd on Friday said its arm Biocon Biologics has been granted a notice of compliance by Health Canada for its biosimilar Yesafili injection used to treat various ailments of the eye. "Health Canada has granted a Notice of Compliance (NOC) for Yesafili(aflibercept), a biosimilar to Eylea injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025," a regulatory filing by Biocon said. This approval paves the way for the launch of Yesafili in Canada, scheduled for July 4, 2025, it said, adding Yesafili is the first biosimilar to Eylea to b ...Read More >
European stocks rose on Friday, heading for small weekly gains, as investors focused on corporate earnings to assess the impact of US tariffs on businesses. The STOXX 600 index climbed 0.3% to 548.84 points, set for its second weekly gain. Other major indexes, including Germany's DAX, France's CAC40, and Britain's FTSE 100, also saw modest increases. Swedish defense company Saab jumped 12.7%, leading the STOXX 600, after reporting better-than-expected second-quarter earnings and raising its sal ...Read More >
New Delhi, Oct 9 (PTI) Drug firm Lupin on Thursday announced the launch of a strategic partnership programme aimed at expanding the reach of a long-acting injectable platform developed by its subsidiary, Nanomi BV. The platform, PrecisionSphere demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent US Food and Drug Administration (USFDA) approval for the first product developed with this platform. The company's partnership programme is designed to foster collaborations with companies looking to extend their product lifecycles, whether in devel ...Read More >
New Delhi, Jul 3 (PTI) Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has been granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases. The marketing authorisation for the European Union (EU) follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025, Biocon Ltd said in a regulatory filing. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and th ...Read More >
Bengaluru: Alembic Pharmaceuticals, Inc., the U.S. subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics Ltd. ("Utility") in a $12 million deal to strengthen its presence in the U.S. market. Alembic will begin the commercialization of Utility's recently FDA approved product Pivya® (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya® was approved by the FDA in April 2024. Commenting on the acquisition, Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, said: "This acquisition gives us a strategic entry into the special ...Read More >
New Delhi, April 4 (SocialNews.XYZ) Union Minister Dr Jitendra Singh met with International Diabetes Federation President-elect Dr Niti Pall, and the latter highlighted that Asian and African countries "are increasingly looking to India for affordable diabetes care solutions," due to leadership in supplying cost-effective vaccines, an official statement said on Saturday. Dr Singh and Dr Pall discussed indigenous biosimilar insulin production and diabetes related indigenous biomanufacturing prospects, the Ministry of Earth Sciences said in a statement. She pointed out that high insulin prices ...Read More >
Biologic therapies are transforming severe asthma treatment by offering the potential for remission, shifting care from symptom control to targeted, personalized approaches. Treatments like dupilumab and tezepelumab have shown efficacy across diverse patient profiles, including complex asthma cases. However, significant barriers remain, particularly cost and access, limiting their availability, especially in underserved communities. Experts stress the need for equitable healthcare solutions to ensure these transformative treatments reach all patients in need. As biologics continue to revolutio ...Read More >
Biopharmaceutical company Boehringer Ingelheim has launched a next generation poultry vaccine for Marek's disease in the country. The product represents a breakthrough in vaccine engineering and recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek's disease, the company said in a release on Tuesday (November 26, 2024). The vaccine offers enhanced protection through an innovative controlled attenuation process, delivering right balance between safety and efficacy. Marek's disease remains a significant ch ...Read More >
New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement. Lupin will be responsible for manufacturing the product and for regulatory submissions, it added. As per the deal, Sandoz will hold exclusive marketing rights in most ...Read More >
Hyderabad, April 4 (RAHNUMA): The Government of India reaffirmed strong support for the pharmaceutical sector at a high-level Chintan Shivir organized by the Department of Commerce and Pharmexcil. The inaugural session was chaired by Rajesh Agrawal, Secretary, Department of Commerce. Senior officials including the Chairman of Pharmexcil and Joint Secretary from the Department of Pharmaceuticals addressed the gathering. The Commerce Secretary, in his address, highlighted the strong growth trajectory of India's pharmaceutical industry, noting that India, with nearly 18-19% of the world's popul ...Read More >
The Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Glenmark as Vice President. This leadership transition occurs as the industry navigates GST reforms and strengthens its global position in specialty medicines. The new team aims to drive innovation, patient access, and quality healthcare solutions. The Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel, Managing Director of Zydus Lifesciences as its new President. Patel succeeds Samir Mehta, Chairman, Torrent Group, the industry body said in an ...Read More >
Bhubaneswar: The Odisha government Tuesday unveiled Pharmaceutical and Medical Devices Policy-2025, aiming to attract investment of Rs 25,000 crore and create 1 lakh jobs by 2030. Chief Minister Mohan Charan Majhi launched the new policy here at the Odisha Pharma Summit-2025 in the presence of Industries Minister Sampad Chandra Swain and senior government officers. Speaking on the occasion, Industries Department's Additional Chief Secretary Hemant Sharma said India imports about 85 per cent of medical devices from other countries, and there is a huge opportunity for this sector. As a lot of ...Read More >
New Delhi, March 31 (SocialNews.XYZ) India's bioeconomy is approaching the $200 billion mark, which is a significant milestone in its evolution with a strong policy push and growing innovation pipeline signalling the next phase of growth, according to a report released on Tuesday. The report by Endiya Partners said that the nation's bioeconomy has expanded sharply from around $10 billion in 2014 to over $195 billion in 2026, now contributing nearly 5 per cent to the GDP. India, long recognised as the 'Pharmacy of the World' for supplying nearly 20 per cent of global generics and over 60 per ...Read More >
New Delhi: The government is working to ensure minimal disruption to supply chains amid global uncertainties, while remaining prepared for a potential dip in exports and imports, Commerce Secretary Rajesh Agrawal said on Saturday. Addressing the press conference on the sidelines of a 'Chintan Shivir' session in Hyderabad, Agrawal told the media that the initiative aims to bring together government and industry stakeholders to identify challenges and chart a clear roadmap. The official also stated that India is focusing on sustaining the growth trajectory of pharmaceutical exports. He said t ...Read More >
HYDERABAD: India's pharmaceutical exports touched nearly USD 28.29 billion by February this financial year, marking a 5.6% growth compared to last year, a top official said at the Chintan Shivir-Scaling up Pharma Exports programme held in Hyderabad on Saturday. Organised by the Pharmaceutical Export Promotion Council of India (Pharmexcil) with support from the Union government, the event was chaired by commerce secretary Rajesh Agarwal, who said India's pharmaceutical industry, valued at around USD 60 billion with nearly 50% exports, has emerged as a global leader due to its scale, cost compe ...Read More >
, /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in from National Medical (TASE:PMCN) Products Administration (NMPA) for the first domestically developed trophoblast cell-surface antigen 2 (TROP2)-directed antibody"drug conjugate (ADC) sacituzumab tirumotecan (sac-™T, formerly SKB264/MK-2870) for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic s ...Read More >
Mumbai, Oct 31 (SocialNews.XYZ) Actress Deepika Padukone, who has been a strong advocate for mental health awareness, reacted to cricketer Jemimah Rodrigues' recent revelation about battling anxiety. The 'Om Shanti Om' actress, known for openly sharing her own struggles with depression in the past, praised Jemimah for her honesty and courage in speaking up, highlighting the importance of conversations around mental well-being in sports and beyond. Taking to her Instagram Stories, Deepika Padukone reshared a video of cricketer Jemimah Rodrigues, in which the athlete opened up about her struggl ...Read More >
Hyderabad, Apr 4 (PTI) India's pharmaceutical exports stood at over USD 28 billion up to February of the current financial year, registering a growth of more than 5 per cent compared to the same period last year, a top official said on Saturday. K Raja Bhanu, Director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), said the sector, currently valued at around USD 60 billion, is projected to grow to USD 130 billion by 2030. "Despite global challenges, pharmaceutical exports have been among the few sectors to maintain growth momentum. Exports during April-February ...Read More >
New Delhi, Apr 4 (PTI) Commerce Secretary Rajesh Agrawal on Saturday asked the pharmaceutical industry to reduce its dependence on critical imported raw materials and diversify export supply chains to better navigate global uncertainties. Addressing an event in Hyderabad on the sector, he said while India exports to around 200 countries, there remains significant scope for expansion and resilience-building through a stronger market presence. Emphasising the need to navigate an increasingly uncertain and geopolitically volatile global environment, he stressed: "the importance of ensuring grea ...Read More >
First & only immuno-oncology drug approved by various regulatory authorities around the world Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In 2023, Dr. Reddy's entered in ...Read More >